In the past week, ALKS stock has gone up by 0.04%, with a monthly gain of 3.38% and a quarterly plunge of -9.64%. The volatility ratio for the week is 2.26%, and the volatility levels for the last 30 days are 2.84% for Alkermes plc The simple moving average for the last 20 days is -1.00% for ALKS stock, with a simple moving average of -7.04% for the last 200 days.
Is It Worth Investing in Alkermes plc (NASDAQ: ALKS) Right Now?
Alkermes plc (NASDAQ: ALKS) has a higher price-to-earnings ratio of 9.54x compared to its average ratio, The 36-month beta value for ALKS is at 0.47. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALKS is 166.76M, and currently, shorts hold a 7.17% of that float. The average trading volume for ALKS on July 03, 2024 was 1.87M shares.
ALKS) stock’s latest price update
Alkermes plc (NASDAQ: ALKS)’s stock price has decreased by -0.82 compared to its previous closing price of 24.39. However, the company has seen a 0.04% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-06-03 that — Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing — DUBLIN, June 3, 2024 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
Analysts’ Opinion of ALKS
Many brokerage firms have already submitted their reports for ALKS stocks, with TD Cowen repeating the rating for ALKS by listing it as a “Buy.” The predicted price for ALKS in the upcoming period, according to TD Cowen is $34 based on the research report published on June 17, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ALKS reach a price target of $37. The rating they have provided for ALKS stocks is “Outperform” according to the report published on March 19th, 2024.
UBS gave a rating of “Sell” to ALKS, setting the target price at $25 in the report published on February 20th of the current year.
ALKS Trading at -0.34% from the 50-Day Moving Average
After a stumble in the market that brought ALKS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.43% of loss for the given period.
Volatility was left at 2.84%, however, over the last 30 days, the volatility rate increased by 2.26%, as shares surge +0.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.43% upper at present.
During the last 5 trading sessions, ALKS rose by +0.04%, which changed the moving average for the period of 200-days by -18.96% in comparison to the 20-day moving average, which settled at $24.44. In addition, Alkermes plc saw -12.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALKS starting from Nichols Christian Todd, who sale 10,417 shares at the price of $28.10 back on Mar 18 ’24. After this action, Nichols Christian Todd now owns 65,911 shares of Alkermes plc, valued at $292,740 using the latest closing price.
Parisi Samuel Joseph, the VP, Finance (Interim PAO) of Alkermes plc, sale 2,559 shares at $29.65 during a trade that took place back on Feb 27 ’24, which means that Parisi Samuel Joseph is holding 7,717 shares at $75,874 based on the most recent closing price.
Stock Fundamentals for ALKS
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.79 for the gross margin
The net margin for Alkermes plc stands at 0.25. The total capital return value is set at 0.23. Equity return is now at value 42.85, with 23.94 for asset returns.
Based on Alkermes plc (ALKS), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at 1.5. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is 16.06.
Currently, EBITDA for the company is 486.73 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 2.34. The receivables turnover for the company is 5.44for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.20.
Conclusion
In conclusion, Alkermes plc (ALKS) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
